Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Lichen Planus (PRELUDE)
NCT04300296Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of secukinumab in lichen planus (LP), sponsored by Novartis. Started Jul 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on NCT04300296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300296.